Increased Surgical Complications but Improved Overall Survival with Adult Living Donor Compared to Deceased Donor Liver Transplantation: A Systematic Review and Meta-Analysis

Table 3

Subgroup analysis.

Outcomes	Subgroup	Studies ()	Effect estimate (95% CI)	value	Heterogeneity	Inconsistency with the overall results
CIT		3	-371.10 (-373.60, -368.60)
		3	-372.02 (-445.71, -298.34)
	Overall	6	-373.39 (-399.41, -347.37)
Vascular complication rates		3	1.05 (0.51, 2.16)			Equivalent
		3	2.89 (1.62, 5.16)
	Overall	6	2.00 (1.31, 3.07)
Biliary complication rates		6	3.71 (1.58-8.71)
		8	1.77 (1.27, 2.48)
		5	4.80 (2.88-7.98)
		9	1.74 (1.24-2.43)
	HCC related	2	2.21 (1.72, 2.83)
	Not HCC related	12	2.21 (1.46, 3.34)
	Overall	14	2.23 (1.59, 3.13)
HCV recurrence		2	1.92 (0.95, 3.87)
		2	0.62 (0.12, 3.15)
	Overall	4	1.10 (0.39, 3.10)
1-year HCC recurrence		3	0.56 (0.35, 0.91)			Favors LDLT
		5	1.29 (0.62, 2.71)
		8	1.00 (0.61, 1.66)
3-year HCC recurrence		2	0.73 (0.46, 1.14)
		3	0.99 (0.44, 2.23)
	Overall	5	0.86 (0.52, 1.41)
5-year HCC recurrence		4	0.70 (0.50, 0.98)			Favors LDLT
		4	1.19 (0.49, 2.90)
	Overall	8	0.87 (0.54, 1.38)
1-year OS		9	1.27 (0.90, 1.77)			Equivalent
		9	1.43 (1.02, 2.01)
	HCC related	9	1.68 (1.19, 2.37)
	Not HCC related	9	1.07 (0.87, 1.32)			Equivalent
	Overall	18	1.32 (1.01, 1.72)
3-year OS		8	1.17 (0.87, 1.58)			Equivalent
		7	1.52 (1.18, 1.95)
	HCC related	9	1.55 (1.17, 2.04)
	Not HCC related	6	1.21 (0.98, 1.50)			Equivalent
	Overall	15	1.39 (1.14, 1.69)
5-year OS		10	1.20 (0.95, 1.52)			Equivalent
		6	1.49 (1.02, 2.16)
	HCC related	10	1.43 (1.01, 2.03)
	Not HCC related	6	1.15 (0.92, 1.42)			Equivalent
	Overall	16	1.33 (1.04, 1.70)